If you’re developing anti-diabetic or gut hormone-related drugs, serotonin reuptake inhibitors, fibroblast growth agonists, or any other therapeutic targeting elements of the musculoskeletal system, it’s crucial to consider what effects these potential therapeutics can have on the system.
Our musculoskeletal toxicology experts answer questions on if a drug compound will potentially affect human bones. They present pathology and juvenile findings to help you understand the evaluation of bone, muscle, and cartilage in efficacy and safety studies.
Aurore Varela, DVM, MSc, DABT
Director, Musculoskeletal Research & Imaging
Martin Guillot, DVM, MSc, PhD
Principal Research Scientist, Musculoskeletal Research
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.